Icagen (ICGN) Senicapoc Fails In Phase IIa Study
More News related to ICGN
- Unusual 11 Mid-Day Movers 01/13: ROSG, ICGN, MRNA, AGEN Higher; FLDR, HEV, RSCR, AMFI Lower
- Icagen to Present at the JP Morgan Healthcare Conference
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
- Morning Movers 10/27: HPGP, HLND, TBAC, CTDC, PODD, HSII Higher; ICGN, AMFI, IBCP, CRI, SGMS, PVTB Lower
- After-Hours Movers 10/26: ENTR, UCTT, LULU, IVAC, TBAC Higher; ICGN, ZRAN, BIDU, WINN, LTD Lower
More News related to FDA
- AspenBio Pharma (APPY) Reports Results from Interim Analysis for Ongoing Trial of AppyScore
- XenoPort (XNPT) Said FDA Moves PDUFA Date Due to February 11
- Dendreon (DNDN) CEO Says Provenge Salesforce Will Be 125 People, Sees Full Manufacturing Ability by Mid-2011
- U.S. FDA to Become More Stringent on Medical Imaging Equipment (GE, SI)
- BSD Medical (BSDM) Initiates Phase 3 Clinical Study of BSD-2000 Hyperthermia System
Icagen, Inc. (Nasdaq: ICGN) reported that in a proof-of-concept, Phase IIa exercise-induced asthma study, senicapoc failed to demonstrate improvement in the primary study endpoints, including maximum decrease in FEV1, time to recovery of FEV1 after exercise and area under the FEV1 curve for sixty minutes.
In this double blind placebo-controlled study, 69 patients were randomized to receive either senicapoc at a maintenance dose of 40 mg/day or placebo. All subjects were tested for pulmonary function following a standardized treadmill exercise regimen at baseline, two and four weeks after treatment. The results of the pulmonary function tests were compared between the treatment groups, adjusting for differences in baseline values.
Although the Company will continue to evaluate the data from this trial, it does not anticipate continuing clinical development of senicapoc at this time.
Related Categories
FDAHot List
Stocks Mentioned
-0.03Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
